News & Updates
Filter by Specialty:
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
Using circulating tumour DNA (ctDNA) analysis to guide adjuvant treatment of stage II colorectal cancer (CRC) reduces adjuvant chemotherapy use without compromising recurrence-free survival (RFS) compared with standard management guided by clinicopathological criteria, results of a phase II randomized controlled trial have shown.
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
05 Jul 2022
Concurrent DOAC, tamoxifen use poses no elevated bleeding risk
In breast cancer patients receiving direct oral anticoagulants (DOACs), tamoxifen is safe to use and does not increase the risk of haemorrhage as compared with concurrent use of an aromatase inhibitor (AI), a study has found.
Concurrent DOAC, tamoxifen use poses no elevated bleeding risk
05 Jul 2022
Deep submucosal invasion not independently linked to metastasis in colorectal cancer
In the absence of other histological risk factors, deep submucosal invasion is not strongly predictive of lymph node metastasis in patients with T1 colorectal cancer, reports a recent meta-analysis.
Deep submucosal invasion not independently linked to metastasis in colorectal cancer
04 Jul 2022
Healthy plant-based diet may reduce breast cancer risk
Adherence to a healthy plant-based diet was tied to a reduced risk of breast cancer, according to a French study presented at Nutrition 2022. In contrast, an unhealthy plant-based diet may be tied to increased breast cancer risk.
Healthy plant-based diet may reduce breast cancer risk
04 Jul 2022
Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma
A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.